CD44 inhibition as a novel therapeutic strategy against T-cell acute lymphoblastic leukemia (T-ALL)

Technology offer: CD44 inhibition as a novel therapeutic strategy against T-cell acute lymphoblastic leukemia (T-ALL)

Reference: TOES20130924007

Summary: Two Spanish research institutions have discovered that the CD44 protein is a therapeutic target in T-cell acute lymphoblastic leukaemia (T-ALL). Binding of a blocking agent such as a monoclonal antibody to the CD44 molecule inhibits the expansion of the leukaemia-initiating cells (LICs) in the bone marrow. Companies interested in a license agreement are sought for.

For more information click here.

Technologické nabídky a poptávky zpracovává BIC Plzeň, partner sítě Enterprise Europe Network.